Abstract
We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation.
Original language | English (US) |
---|---|
Article number | ofab050 |
Journal | Open Forum Infectious Diseases |
Volume | 8 |
Issue number | 2 |
DOIs | |
State | Published - Feb 1 2021 |
Bibliographical note
Publisher Copyright:© 2021 The Author(s).
Keywords
- COVID-19
- SARS-COV-2
- cohort
- coronavirus
- fluvoxamine